Clinical trials: Bleeding Diathesis
Blood Loss, Surgical, Coagulation Disorder
Phase 3 Trial of Reltodecacog Alfa (VMX-C001) vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin.
The goal of this clinical trial is to learn if reltodecacog alfa (VMX-C001) works to to allow blood clotting control in participants who take FXa Direct Oral Anticoagulants (DOACs) during surgery or other invasive procedures that…
- Trial name
- EQUILIBRIX-S (NCT07288489)
- Testing
- Reltodecacog alfa, Usual Pharmacological Care
- Where
- 77 sites in United States, Australia and 16 more
- Volunteers
- 800 people
- Sponsor
- VarmX B.V.
Refractory Immune Cytopenia
BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR T cells in patients with refractory ITP associated with autoimmune disease.
- Trial name
- NCT06787989
- Testing
- BCMA-CD19 cCAR T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Primary Immune Thrombocytopenia
Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine
The purpose of this study is to assess the ability of Atorvastatin and N-acetyl cysteine to elevate the blood (serum) platelet count in patients with Immune Thrombocytopenia as a mean of a new treatment.
- Trial name
- NCT05551624
- Testing
- Atorvastatin 40 Mg Oral Tablet + N-acetylcysteine 400 mg Oral tablet
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Hospital Civil de Guadalajara
Cutaneous Vasculitis
IgA-positive Versus IgA-negative Immune Complex Vasculitis
Cutaneous vasculitis due to vascular deposition of large circulating immune complexes is a disease frequently seen by general practitioners and dermatologists.
- Trial name
- NCT01815190
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Blood Coagulation Disorder
Biomarkers and Prediction of Tigecycline Induced Coagulation Dysfunction
This study is to screen out the biomarkers and establish the model to predict coagulation dysfunction induced tigecycline
- Trial name
- NCT05698160
- Volunteers
- 200 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Von Willebrand Disease, Menorrhagia
The Effect of the Nutraceutical "Hemofix" on the Coagulation System
Hemofix is a herbal formula based on traditional Jewish and far eastern medicine created to assist in wound healing and bleeding arrest. It contains herbs such as Red Clover, Liquorice, Raspberry, Ginger and more.
- Trial name
- NCT01651468
- Testing
- HEMOFIX
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Hemophilia A
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
To evaluate the effect of secondary prophylaxis as compared to episodic treatment on bleeding frequency (number of bleeds per year) and on joint damage.
- Trial name
- SPINART (NCT00623480)
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- 38 sites in United States, Argentina and 2 more
- Volunteers
- 84 people
- Sponsor
- Bayer
Immune Thrombocytopenia
Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia
Hydroxychloroquine has been reported to have a clinically significant effect on the platelet count in systemic lupus thrombocytopenia. Its action may be due to its immune modulator effect.
- Trial name
- NCT03229746
- Testing
- Hydroxychloroquine, vincristine, azathioprine
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Immune Thrombocytopenic Purpura (ITP)
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a lower number of platelets, making it easier to bruise or bleed.
- Trial name
- NCT06948318
- Testing
- Mezagitamab
- Where
- 118 sites in United States, Australia and 13 more
- Volunteers
- 150 people
- Sponsor
- Takeda
Healthy Subjects, Purpura, Thrombocytopenic, Idiopathic
Eltrombopag Taste Testing in Healthy Adult Volunteers
Based on a need for a pediatric formulation of eltrombopag for the treatment of pediatric thrombocytopenia, this study will help determine the best tasting pediatric formulation of eltrombopag.
- Trial name
- NCT00487968
- Testing
- eltrombopag
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Thrombocytopenia, Immune Thrombocytopenia
Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP
The purpose of this study is to evaluate the efficacy and safety of rhTPO in the maintenance treatment of ITP, to explore the appropriate dosing interval of the maintenance treatment of rhTPO .
- Conditions
- Thrombocytopenia, Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura
- Trial name
- NCT01805648
- Testing
- rhTPO
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College
Chronic Myeloproliferative Disorders, Leukemia
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Nonneoplastic Condition
- Trial name
- NCT00132015
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery
This study is conducted in Japan. The aim of this non-interventional study is to investigate the safety and effectiveness of treatment with eptacog alpha (NovoSeven®) when undergoing surgery under normal clinical practice…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- NCT01579968
- Testing
- eptacog alfa (activated)
- Where
- Japan
- Volunteers
- 86 people
- Sponsor
- Novo Nordisk A/S
Hemophilia a
A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic Prophylaxis (Efa Emi Bone Health Study)
This study will compare bone mineral density in patients with severe hemophilia A receiving prophylaxis with emicizumab or efanesoctocog alfa.
- Trial name
- NCT07582276
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Arkansas Children's Hospital Research Institute
Thrombocytopenia, Idiopathic Thrombocytopenic Purpura
Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP)
The purpose of this study is to evaluate changes in bone marrow morphology (structure) after long-term exposure to romiplostim.
- Trial name
- NCT00907478
- Testing
- romiplostim
- Volunteers
- 169 people
- Sponsor
- Amgen
Pulmonary Artery Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension
The objective of the present study is to assess blood coagulation disorders in patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension.
- Trial name
- NCT03195543
- Testing
- Platelet function analyzer-100, Light transmission aggregometry, Rotational thromboelastometry
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National and Kapodistrian University of Athens
Hemophilia A, Hemophilia B
Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors
This is the first in humans study of BAY86-6150 (B0189) in non-bleeding subjects with moderate or severe congenital hemophilia A or B with or without inhibitors.
- Trial name
- MATCHBOX (NCT01921855)
- Testing
- BAY Factor VII (BAY86-6150)
- Where
- 4 sites in Poland, South Africa and 1 more
- Volunteers
- 16 people
- Sponsor
- Bayer
Hyperfibrinogenemia, Hemostatic Disorder
Coagulation Disorders Secondary to Two Plasmapheresis Techniques (Double Filtration Plasmapheresis vs. PFS). Descriptive Pilot Study.
Therapeutic plasmapheresis causes changes in haemostasis by purifying many of the circulating factors involved. Few reliable data are available on these changes and most studies are limited to coagulation factor assays before and…
- Trial name
- APHERCOAG (NCT06571552)
- Testing
- Single Plasma Exchange followed by Double Filtration Plasmapheresis
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Immune Thrombocytopenia, Treatment
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with rituximab in ITP patients.This study will be conducted in ITP patients who had not responded to or had…
- Trial name
- NCT07297563
- Testing
- Rituximab, Daratumumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Uterine Bleeding Disorders, Benign Uterine Conditions
Comparison of BiCision® Versus UltraCision® During Laparoscopic Supracervical Hysterectomy (LASH)
The aim of the study is the evaluation of the efficiency and safety of the new, CE-certified thermofu-sion and dissection instrument BiCision® in comparison with the long established Ultracision® Har-monic Scalpel(Ethicon)during…
- Conditions
- Uterine Bleeding Disorders, Benign Uterine Conditions, Focus: Comparison of Two Instruments
- Trial name
- NCT01752725
- Testing
- BiCision®, Ultracision® Har-monic Scalpel(Ethicon)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Hospital Tuebingen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.